From the Shoulders of a Giant

Premium

Looks like Shimadzu wants to join in the proteomics games. The company just spun out Shimadzu Biotech, headquartered in Kyoto, Japan, and led by its former head of life sciences, Tetsuo Ichikawa. The spinoff is “not a single corporation but a strategic global unit,” Ichikawa says; it will draw on the parent company’s subsidiaries in the US, Europe, and Australia. Shimadzu Biotech inherits a $43 million business in bioscience and expects that to grow to more than $170 million within three years.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.